

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
23 December 2021 (23.12.2021)



(10) International Publication Number
WO 2021/255138 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) C07K 16/24 (2006.01)
C07K 16/42 (2006.01) C07K 14/705 (2006.01)
A61K 47/68 (2017.01) C07K 14/55 (2006.01)
A61P 35/00 (2006.01) A61K 39/395 (2006.01)

(21) International Application Number:

PCT/EP2021/066337

(22) International Filing Date:

17 June 2021 (17.06.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20181087.6 19 June 2020 (19.06.2020) EP

(71) Applicant (for all designated States except US): **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, 4070 Basel (CH).

(71) Applicant (for US only): **HOFFMANN-LA ROCHE INC.** [US/US]; Overlook at Great Notch, 150 Clove Road 8th Floor, Suite 8 - Legal Department, Little Falls, New Jersey 07424 (US).

(72) Inventors: **AMANN, Maria**; c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). **CARPY GUTIERREZ CIRLOS, Alejandro**; c/o Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg (DE). **CLAUS, Christina**; c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). **CODARRI DEAK, Laura**; c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). **DAROWSKI, Diana**; c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). **FAUTI, Tanja**; c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). **FERRARA KOLLER, Claudia**; c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). **FREIMOSER-GRUNDSCHOBBER, Anne**; c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). **HERTER, Sylvia**; c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). **HOFER, Thomas**; c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). **KLEIN, Christian**; c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). **LAUENER, Laura**; c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). **LECLAIR, Stephane**; c/o Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg (DE). **MOESSNER, Ekkehard**; c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). **NEUMANN, Christiane**; c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). **UMAÑA, Pablo**; c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH).

(74) Agent: **BUSER, Andres**; Grenzacherstrasse 124, 4070 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
— with sequence listing part of description (Rule 5.2(a))

(54) Title: IMMUNE ACTIVATING FC DOMAIN BINDING MOLECULES

(57) Abstract: The present invention generally relates to novel immune activating Fc domain binding molecules for activation of immune cells and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.

WO 2021/255138 A1